Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01953315 · ClinicalTrials.gov registry record · Phase 1
Muscle Progenitor Cell Therapy for Urinary Incontinence
A Phase 1 study of Urinary Incontinence, sponsored by Wake Forest University.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 2
- Study locations
NCT01953315 is a Phase 1 study of Urinary Incontinence that has completed, run by Wake Forest University. The registered enrollment target is 10 participants, below the 262-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT01953315, a Phase 1 study of Urinary Incontinence, has completed, sponsored by Wake Forest University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is designed to evaluate the safety of muscle progenitor cells (MPCs) for the treatment of urinary incontinence due to incompetent outlet (bladder neck/urethra).
Conditions Studied
Interventions
- BIOLOGICAL Autologous Muscle Progenitor Cells
Study Locations (2)
North Carolina
- Wake Forest Urology Clinic - Winston-Salem
- Wake Forest Institute for Regenerative Medicine (WFIRM) - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2014-01 |
| Est. Completion | 2018-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01953315
The ClinicalTrials.gov registry entry for NCT01953315 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 262-participant average among 48 other Urinary Incontinence trials with a reported enrollment target (96% lower). The listed sponsor is Wake Forest University, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Urinary Incontinence appearing as the primary indexed condition, and to 1 intervention - of which Autologous Muscle Progenitor Cells is the first listed.
NCT01953315 reports 2 study locations spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT01953315 about?
NCT01953315 is a clinical study titled "Muscle Progenitor Cell Therapy for Urinary Incontinence". This study is designed to evaluate the safety of muscle progenitor cells (MPCs) for the treatment of urinary incontinence due to incompetent outlet (bladder neck/urethra).
What is the current status of trial NCT01953315?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2014-01. Estimated completion is 2018-01.
What conditions does trial NCT01953315 study?
This clinical trial studies the following conditions: Urinary Incontinence.
What interventions are being tested in trial NCT01953315?
The interventions under investigation include: Autologous Muscle Progenitor Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT01953315?
This trial is sponsored by Wake Forest University, which has 100 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01953315 being conducted?
This trial has 2 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Urinary Incontinence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Muscle Fiber Fragment Treatment for Urinary Incontinence
RECRUITING · Phase 1
-
Use of Sildenafil for Treatment of Urinary Incontinence
ACTIVE NOT RECRUITING · Phase 1
-
NXT Post-Market Clinical Follow-up
RECRUITING
-
Trial of Transurethral Bulking Agent Injection Versus Single-Incision Sling for Stress Urinary Incontinence
RECRUITING · NA
-
TENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence.
RECRUITING · NA
-
Adjustable Continence Therapy (ACT) for the Treatment of Female SUI
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.